Atara Biotherapeutics, Inc.

What they do

Atara develops off-the-shelf allogeneic T-cell therapies based on an Epstein-Barr virus (EBV) T-cell platform. Its lead product, tabelecleucel (tab-cel), is approved as Ebvallo in the European Economic Area, UK and Switzerland for EBV+ post-transplant lymphoproliferative disease (EBV+ PTLD) and is in Phase 3 development in the U.S. The company partners with Pierre Fabre Medicament for commercialization in Europe and worldwide rights, and has discontinued CAR T operations for ATA3219 and ATA3431 and stopped development of ATA188 in multiple sclerosis.

Revenue drivers

• Tabelecleucel (Ebvallo) royalties and milestones — Atara is eligible for tiered double-digit royalties on Ebvallo net sales and a $31 million milestone on FDA approval of the tabelecleucel BLA, under the Pierre Fabre commercialization agreement. A portion of European royalties and milestones is owed to HCRx under a 2022 royalty monetization.
• Pierre Fabre collaboration revenue — Historically the largest revenue line, including the accelerated recognition of deferred revenue in 2025 following transition of development activities to Pierre Fabre Laboratories. This source fell sharply year over year and left little deferred revenue to recognize in 2026.
• Other EBV-driven disease pipeline — Tab-cel is also in development for other EBV-driven diseases beyond EBV+ PTLD, but these programs have not generated product revenue.
• Discontinued programs (no ongoing revenue) — CAR T programs ATA3219 and ATA3431 and the MS program ATA188 have been paused or stopped, so they contribute no revenue.

Recent performance

For the second quarter of 2026, Atara reported total revenues of $0.6 million versus $17.6 million in the prior-year period, a $17.0 million decline attributed primarily to accelerated recognition of deferred revenue in 2025 after development activities transitioned to Pierre Fabre. R&D expenses fell to $1.3 million from $7.3 million and G&A to $3.8 million from $6.5 million; total costs and operating expenses were down 87% year over year. Net loss was $4.8 million, or $0.32 per share, compared with net income of $2.4 million in the second quarter of 2025. Cash, cash equivalents and short-term investments totaled $9.9 million at June 30, 2026, up from $8.4 million at March 31, 2026, with net cash used in operations of $3.3 million for the quarter.

Strategy

Management is focused on supporting Pierre Fabre's planned resubmission of the tabelecleucel BLA to the FDA based on the existing Phase 3 single-arm ALLELE trial, following a productive Type A meeting. It is also pursuing cost reductions; operating expenses are expected to decline significantly year over year from initiatives implemented in 2025 and the first half of 2026. The company has deprioritized or stopped its CAR T and MS programs, and says it is taking steps to control expenses to protect shareholder value and enhance strategic flexibility.

Risks

• Going concern and thin liquidity —
• FDA approval and resubmission risk —
• Revenue decline and dependence on Pierre Fabre —
• Listing-rule failure —

Outlook

Atara expects operating expenses to decline significantly year over year as the full benefit of 2025 and first-half 2026 cost reductions is realized. Management says cash, cash equivalents and short-term investments as of June 30, 2026, combined with these efficiencies, will fund planned operations into mid-2027. The company anticipates a further regulatory update on the tabelecleucel BLA resubmission later in the quarter. It continues to describe significant U.S. commercial potential for tab-cel if approved.